ClinicalTrials.gg
RecruitingNCT07172464PROTEA-PFOUpdated Nov 19, 2026

Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study

An interventional study of Recross P3 Occluder (P3O) System in PFO, PFO - Patent Foramen Ovale and Cryptogenic Stroke, sponsored by Recross Cardio, Inc.. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Recross Cardio, Inc. · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 19, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies in Foramen Ovale, Patent with a site in United States — 10 open to participants now, 12 under way, 1 of them phase 3. Foramen Ovale, Patent · United States.

Planned enrollment
20th of 25
30 · median 168
Started
2025
the only one that year
No phase
15 of 36
5 open now
Primary completion
2027-08
later than 6 of 11 live
Registered
32nd of 36
by date

Among the 36 studies in Foramen Ovale, Patent with a site in United States, this one is the 20th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2025, is one of 15 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 32nd registered.

Foramen Ovale, Patent

137 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.

Browse Foramen Ovale, Patent studies →

Open to participants now

10 of the 36 studies in Foramen Ovale, Patent with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Foramen Ovale, Patent studies recruiting now, 11 (32%) set no upper age limit and 19 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Foramen Ovale, Patent with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test a new heart device called P3 Occluder System in patients who have a small opening between the upper chambers of the heart (called a Patent Foramen Ovale or PFO) and have experienced a stroke that may be related to this heart opening. The main question it aims to answer is:

  • Is the P3 Occluder System safe and effective for closing a PFO in patients who have had a stroke that could be related to a PFO.

Participants will:

  • Undergo the procedure to implant the P3 Occluder System, if deemed appropriate.
  • Visit their doctor at 1 month, 3 months, 6 months, 1 year and 5 years after the procedure for follow up exams.
  • Answer a phone call from study staff at 2 years, 3 years and 4 years after the procedure to answer a survey.
03

Conditions studied

  • PFO
  • PFO - Patent Foramen Ovale
  • Cryptogenic Stroke
  • Patent Foramen Ovale
  • PFO-associated Stroke

Keywords

  • Patent Foramen Ovale
  • PFO
  • Cryptogenic Stroke
  • PFO Occluder
  • Transcatheter
  • PFO-associated stroke
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must be ≥ 18 and ≤ 65 years of age
  2. Diagnosis of PFO, defined as visualization of microbubbles per TEE in the left atrium within three cardiac cycles from the right atrial opacification demonstrating right-to-left shunting at rest and/or during Valsalva release.
  3. Ischemic stroke, defined as acute focal neurological deficit, presumed to be due to focal ischemia and confirmed by MRI or CT to have a neuroanatomically relevant cerebral infarct.
  4. Modified Rankin score (mRS) ≤ 3.
  5. Appropriate PFO anatomy for implantation of the device as evaluated and determined by independent committee.
  6. Patient is willing and capable of providing .
  7. Prior to index procedure (7-day window), persons of must have a negative pregnancy test.

Exclusion criteria

Exclusion Criteria:

  1. Other identifiable causes of stroke, including but not limited to aortic arch plaques (protruding >4 mm into the lumen), large artery atherosclerotic disease proximal to the territory of the index stroke, an established cardioembolic source, small-vessel occlusive disease, or arterial dissection, presence of left atrial appendage thrombus.
  2. Other arteriopathy of the intracranial or extracranial vessels with >50% stenosis proximal to the territory of the index stroke.
  3. Intracardiac thrombus or tumor.
  4. Myocardial Infarction (MI) or unstable angina within the previous 180 days.
  5. \< 2 years.
  6. Left ventricular aneurysm or akinesis.
  7. Moderate to severe mitral valve stenosis or severe mitral regurgitation.
  8. Aortic valve stenosis (mean gradient >20 mmHg) or severe regurgitation.
  9. Active endocarditis or other infection that may preclude implantation of the device.
  10. Any valve vegetation or Lambl's excrescence of any left-sided valve.
  11. Left ventricular dilated cardiomyopathy with \<35%.
  12. Another source of right-to-left shunts identified at baseline, including an atrial septal defect and/or fenestrated septum and pulmonary arteriovenous malformation.
  13. History of atrial tachycardia, atrial fibrillation or flutter, AV block, or ventricular arrhythmia requiring antiarrhythmic medication, pacemaker, or AICD.
  14. Severe renal failure ( Stage 4 CKD, \<30) or patient requiring dialysis.
  15. Severe liver disease (e.g., documented cirrhosis or active hepatitis).
  16. Severe lung insufficiency (e.g., need for supplemental oxygen or chronic medications).
  17. Uncontrolled hypertension, defined as sustained elevated blood pressure >140/90 mm Hg.
  18. Severe pulmonary artery hypertension, defined as pulmonary systolic pressure of >50mmHg.
  19. Uncontrolled hyperglycemia, defined as value >8% (IFCC: >64 mmol/mol).
  20. Increased bleeding risk such as severe liver failure, active peptic ulcer, proliferative diabetic retinopathy, history of severe bleeding (e.g.: gastrointestinal bleeding, macroscopic hematuria, intraocular bleeding, intracranial or cerebral hemorrhage), or other history of bleeding or coagulopathy.
  21. Known hypercoagulable state that would require full anticoagulation. Minimum testing to include lupus anticoagulant, anticardiolipin antibodies, beta-2-glycoprotein, homocysteine.
  22. Subjects for aspirin or clopidogrel.
  23. Subjects not able to discontinue anticoagulation for indications other than then index stroke.
  24. Any disorder in the investigator's opinion that could interfere with compliance of safety evaluation or require premature discontinuation of antiplatelet regime post-implantation, as well as any severe concurrent illness that would limit life expectancy (e.g., ).
  25. Currently an active subject in an investigational drug or device study that could confound the results of this study.
  26. Any significant valve dysfunction that contraindicates PFO closure or increased pulmonary vascular resistance/severe pulmonary hypertension.
  27. Contraindication for transesophageal echocardiography (TEE) or intracardiac echocardiography (ICE).
  28. Any prior percutaneous cardiovascular intervention for AF ablation.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Recross P3 Occluder (P3O) System

    The Recross P3 Occluder (P3O) is being developed for the purpose of transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients with PFO-associated stroke.

    Device: Recross P3 Occluder (P3O) System

Interventions

  • DeviceRecross P3 Occluder (P3O) System

    The Recross P3 Occluder (P3O) is being developed for the purpose of transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients with PFO-associated stroke.

06

What researchers measure

Primary outcomes

  1. Primary Safety Endpoint - Rate of Major Adverse Cardiovascular Events (MACE)

    Rate of Major Adverse Cardiovascular Events (MACE) at 30 days post-procedure, defined as the composite of cardiac death (CD), myocardial infarction (MI), and stroke events.

    Time frame: 30 days

  2. Primary Performance Endpoint - Effective PFO Closure

    Effective PFO Closure, at index procedure and at 6 months as measured by TEE, as adjudicated.

    Time frame: 6 months

Secondary outcomes

  1. Secondary Safety Endpoints - Rate of device-related or procedure-related Serious Adverse Events (SAEs)

    Rate of device-related or procedure-related Serious Adverse Events (SAEs) at 30 days. Rate of device-related or procedure-related Serious Adverse Events (SAEs) at 6 months.

    Time frame: 30 days; 6 months

  2. Secondary Performance Endpoint - Correct device position

    Correct device position as assessed at 6 months on echocardiography, assessed by TTE or TEE.

    Time frame: 6 months

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Aug 2027, 22 months after the start.

Of 31 interventional studies with no phase under Foramen Ovale, Patent, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 100. This study's planned 22 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Aug 2026 → Aug 2027 and completion Feb 2031 → Feb 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2025
First posted
Sep 15, 2025
StartActual
Oct 9, 2025
Primary completionEst.
Aug 2027was Aug 2026
CompletionEst.
Feb 2032was Feb 2031
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • Columbia University Medical Center/ NewYork Presbyterian Hospital · New York, United States
Nov 19, 2026
Primary completion
Aug 2026→Aug 2027
Nov 19, 2026
Study completion
Feb 2031→Feb 2032
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    1 site removed
    Show 1 removed
    • Columbia University Medical Center/ NewYork Presbyterian Hospital · New York, United States
    Primary completion Aug 2026→Aug 2027
    Study completion Feb 2031→Feb 2032
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07172464
Lead sponsor
Recross Cardio, Inc.
Collaborators
MCRA
Responsible party
Sponsor
First posted
Sep 15, 2025
Start date
Oct 9, 2025
Primary completion
Aug 2027 (estimated)
Completion
Feb 2032 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion